LianBio (NASDAQ:LIAN – Get Free Report) fell 1.6% on Tuesday . The company traded as low as $0.26 and last traded at $0.27. 8,742 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 1,037,083 shares. The stock had previously closed at $0.27.
LianBio Price Performance
The company has a market cap of $29.17 million, a price-to-earnings ratio of -0.33 and a beta of 0.23. The company’s 50-day simple moving average is $0.28 and its 200-day simple moving average is $0.30.
About LianBio
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.
See Also
- Five stocks we like better than LianBio
- 3 Dividend Kings To Consider
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- ETF Screener: Uses and Step-by-Step Guide
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- 3 Fintech Stocks With Good 2021 Prospects
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.
